And yet another deal.
US biopharma, Acadia Therapeutics, has announced a collaboration with Stoke Therapeutics to discover, develop and commercialise ASO therapies targeting three rare neurodevelopmental diseases.
Acadia is paying US$60m upfront and Stoke is eligible to receive up to US$907 million in milestones as well as royalties on future sales.
Stoke’s leading compound (targeting Dravet syndrome) is currently in a Phase 1/2 trial. Stoke has only recently released interim data from that trial, suggesting that the drug is safe and demonstrating efficacy signals at the earlier, lower doses.
https://investor.stoketherapeutics....armaceuticals-and-stoke-therapeutics-announce
https://www.fiercebiotech.com/biote...line-60m-central-nervous-system-research-pact
And yet another deal. US biopharma, Acadia Therapeutics, has...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |